Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Lumen Bioscience Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, Catherine Anne Konopka. The portfolio is currently active in 1 distinct art unit, which provides a singular point of focus for the company's biotechnology patenting efforts. This concentration allows for a specialized approach to the 1 pending office action.
Catherine Anne Konopka is the busiest examiner for this company, currently managing 1 pending office action. With 1 distinct examiner and 1 pending office action, the prosecution process is entirely centralized under this individual. The 1 distinct art unit involved provides the technical framework for the 1 pending office action within the Biotechnology & Pharmaceuticals field. This means that the company's current success in this sector is dependent on the specific assessment of Catherine Anne Konopka. The singular nature of the 1 pending action and 1 examiner simplifies the communication but places significant weight on the examiner's personal interpretation of pharmaceutical patent standards.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18767011 | TARGETED MUTAGENESIS IN SPIRULINA | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18767011 | TARGETED MUTAGENESIS IN SPIRULINA | KONOPKA, CATHERINE ANNE | 1635 | §103 | Final Rejection | — | Pending | Jul 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial